S&P 500

5.745,37

0,40%

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

PTN

Palatin Technologies (PTN)

Palatin Technologies Inc New

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:PTN

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
26/09/2024	13h30	PR Newswire (US)	Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results	AMEX:PTN	Palatin Technologies Inc New
09/09/2024	13h30	PR Newswire (US)	Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones	AMEX:PTN	Palatin Technologies Inc New
06/09/2024	22h35	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:PTN	Palatin Technologies Inc New
28/08/2024	13h30	PR Newswire (US)	FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)	AMEX:PTN	Palatin Technologies Inc New
22/08/2024	13h30	PR Newswire (US)	First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity	AMEX:PTN	Palatin Technologies Inc New
02/08/2024	23h01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
31/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
31/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
25/07/2024	22h46	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	AMEX:PTN	Palatin Technologies Inc New
17/07/2024	17h14	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
16/07/2024	22h31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
21/06/2024	14h00	PR Newswire (US)	Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds	AMEX:PTN	Palatin Technologies Inc New
20/06/2024	13h30	PR Newswire (US)	Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)	AMEX:PTN	Palatin Technologies Inc New
12/06/2024	13h30	PR Newswire (US)	Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity	AMEX:PTN	Palatin Technologies Inc New
15/05/2024	14h40	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:PTN	Palatin Technologies Inc New
15/05/2024	14h04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:PTN	Palatin Technologies Inc New
15/05/2024	13h30	PR Newswire (US)	Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update	AMEX:PTN	Palatin Technologies Inc New
09/05/2024	13h30	PR Newswire (US)	Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024	AMEX:PTN	Palatin Technologies Inc New
02/05/2024	13h30	PR Newswire (US)	Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity	AMEX:PTN	Palatin Technologies Inc New
30/04/2024	13h30	PR Newswire (US)	Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024	AMEX:PTN	Palatin Technologies Inc New
08/04/2024	13h30	PR Newswire (US)	Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024	AMEX:PTN	Palatin Technologies Inc New
07/03/2024	23h02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:PTN	Palatin Technologies Inc New
04/03/2024	18h57	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	AMEX:PTN	Palatin Technologies Inc New